These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30786212)

  • 1. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
    Hale ME; Moe D; Bond M; Gasior M; Malamut R
    Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse-deterrent Opioid Formulations.
    Litman RS; Pagán OH; Cicero TJ
    Anesthesiology; 2018 May; 128(5):1015-1026. PubMed ID: 29252508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.
    Mastropietro DJ; Omidian H
    Expert Opin Pharmacother; 2015 Feb; 16(3):305-23. PubMed ID: 25421961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview.
    Butreddy A; Nyavanandi D; Narala S; Austin F; Bandari S
    Curr Drug Deliv; 2021; 18(1):4-18. PubMed ID: 32811398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
    Schaeffer T
    J Med Toxicol; 2012 Dec; 8(4):400-7. PubMed ID: 23073726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing.
    Altomare C; Kinzler ER; Buchhalter AR; Cone EJ; Costantino A
    J Opioid Manag; 2017; 13(6):441-448. PubMed ID: 29308590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.
    Miller CJ; Dart RC; Katz NP; Webster LR
    J Opioid Manag; 2017; 13(6):379-389. PubMed ID: 29308585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process.
    Bhola J; Borkhataria C
    Pharm Dev Technol; 2024 Oct; 29(8):824-831. PubMed ID: 39206465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.